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Clinical PerspectiveWhat Is New?There were no clinically significant differences in 1‐year health status outcomes or improvement in health status by sex among patients without acute myocardial infarction following percutaneous coronary intervention.Female sex was associated with poorer 1‐year health status and a lower likelihood of experiencing clinically improvement in health status.What Are the Clinical Implications?Women can benefit as much as men from percutaneous coronary intervention with regard to their unadjusted health status outcomes.Further studies are needed to clarify the association between sex and health status following percutaneous coronary intervention.

Introduction {#jah34896-sec-0009}
============

Percutaneous coronary intervention (PCI) is a cornerstone in the treatment for patients with coronary artery disease (CAD), including those with and without acute myocardial infarction (AMI). Unlike patients with AMI, those undergoing PCI for stable coronary disease have substantially lower risks for death and major cardiovascular events, especially given the wide use of more‐sensitive biomarkers of myocardial necrosis, such as troponins, as the key criteria for diagnosing AMI. Therefore, improving health status--related (symptoms, functioning, and quality of life) outcomes have become increasingly important for these patients.

Earlier studies have shown improved health status following PCI among stable patients.[1](#jah34896-bib-0001){ref-type="ref"}, [2](#jah34896-bib-0002){ref-type="ref"}, [3](#jah34896-bib-0003){ref-type="ref"}, [4](#jah34896-bib-0004){ref-type="ref"}, [5](#jah34896-bib-0005){ref-type="ref"}, [6](#jah34896-bib-0006){ref-type="ref"}, [7](#jah34896-bib-0007){ref-type="ref"} However, these studies did not stratify the population by sex. Whether women can benefit as much as men from PCI with regard to their health status outcomes remains unclear. Among patients undergoing PCI, women tend to have worse socioeconomic status than men and hence may experience greater barriers to access to follow‐up care and have poor adherence to medications after discharge.[8](#jah34896-bib-0008){ref-type="ref"}, [9](#jah34896-bib-0009){ref-type="ref"}, [10](#jah34896-bib-0010){ref-type="ref"} Moreover, women more likely have other comorbidities and microvascular dysfunction, where PCI may be less effective in relieving symptoms.[11](#jah34896-bib-0011){ref-type="ref"} Thus, it is possible that women may have more residual symptoms and worse quality of life after PCI compared with men.[8](#jah34896-bib-0008){ref-type="ref"}, [9](#jah34896-bib-0009){ref-type="ref"}, [10](#jah34896-bib-0010){ref-type="ref"}, [12](#jah34896-bib-0012){ref-type="ref"}, [13](#jah34896-bib-0013){ref-type="ref"} However, data on sex‐based differences in such outcomes for patients without AMI are sparse.[1](#jah34896-bib-0001){ref-type="ref"}, [14](#jah34896-bib-0014){ref-type="ref"}, [15](#jah34896-bib-0015){ref-type="ref"}, [16](#jah34896-bib-0016){ref-type="ref"}

Data from China can provide a unique opportunity for investigating sex differences in patients' health status after PCI. The volume of PCI procedures has increased substantially over the past decade, reaching 915 256 procedures in 2018, with 65% performed among patients without AMI.[17](#jah34896-bib-0017){ref-type="ref"}, [18](#jah34896-bib-0018){ref-type="ref"}, [19](#jah34896-bib-0019){ref-type="ref"}, [20](#jah34896-bib-0020){ref-type="ref"}, [21](#jah34896-bib-0021){ref-type="ref"} Understanding how women and men differ in symptoms and quality of life after PCI may help guide clinical decision making regarding PCI and inform better tailored care for the large number of women undergoing these procedures in China. Such information may also inform care for women in Western countries.

Using data from the China PEACE‐Prospective PCI Study (China Patient‐centered Evaluative Assessment of Cardiac Events Prospective Percutaneous Coronary Intervention Study), we sought to determine whether: (1) women have similar health status at 1 year after PCI among patients without AMI; (2) improvement in health status from baseline to 1 year following PCI differs by sex; and (3) such sex differences persist after adjustment for patients' sociodemographics, clinical characteristics, treatment factors, and baseline health status.

Methods {#jah34896-sec-0010}
=======

Disclosure Statement The data and statistical code are not available to other researchers at this time.

Study Population and Study Design {#jah34896-sec-0011}
---------------------------------

The design of the China PEACE‐Prospective PCI Study has been published previously.[22](#jah34896-bib-0022){ref-type="ref"} In brief, between 2012 and 2013, we enrolled 4225 consecutive patients undergoing PCI for CAD who had at least 1 coronary stent implanted at 40 sites (39 participating tertiary hospitals) located in 18 provinces in China. For this study, we excluded patients who died during hospitalization (n=11), those with treatment withdrawal because of serious illness (n=1), those who were transferred out (n=8), and those with AMI (n=1968) and focused on participants without AMI (n=2237), including those with unstable angina (UA; n=1599) or stable CAD (n=638). Diagnosis of AMI was determined by the clinical discharge diagnosis terms recorded in medical charts.

The central ethics committee at the China National Centre of Cardiovascular Disease, local ethics committee at each participating hospital, and the Yale University Human Investigation Committee approved this study. The Chinese government funded the study and had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The study was registered on <http://www.clinicaltrials.gov> (NCT01624922).

Data Collection and Variable Definitions {#jah34896-sec-0012}
----------------------------------------

We collected patients' baseline characteristics and in‐hospital treatment and complications by central medical chart abstraction and in‐person interview by trained site investigators during the index hospitalization. Patients' baseline characteristics included social demographics, cardiac risk factors, comorbidities, and disease severity at admission. In‐hospital treatment included number of vessels treated, complete versus incomplete revascularization, type of sent placed, access site, and medications used. In‐hospital complications included AMI, stroke, target vessel revascularization, and bleeding events. Complete revascularization was defined as absence of diameter stenosis ≥50% in major coronary arteries or their side branches with a diameter ≥2.5 mm after successful stent implantation during index hospitalization. In contrast, incomplete revascularization was defined as the presence of diameter stenosis ≥50% in major coronary arteries or their side branches with a diameter ≥2.5 mm after successful stent implantation during index hospitalization.

We collected data on patients' clinical outcomes from discharge to 1 year. In addition, we conducted follow‐up interviews at 1, 6, and 12 month after index hospitalization to characterize clinical outcomes and health status using validated patient‐reported outcome measures. For this study, we focused on 12‐month outcomes. Clinical outcomes included all‐cause death, cardiac death, nonfatal AMI, ischemic stroke, coronary revascularization, and a composite of major adverse cardiac events (including cardiac death, nonfatal AMI, ischemic stroke, and coronary revascularization). All the clinical cardiac events were adjudicated by trained cardiologists. Disease‐specific (Seattle Angina Questionnaires \[SAQ\]) health status instruments translated into Chinese were administered by trained site investigators. If the relative of the patients, rather than the patient him‐ or herself answered phone survey, only the clinical outcomes were collected.

The SAQ is a 19‐item disease‐specific health status measure for patients with CAD.[23](#jah34896-bib-0023){ref-type="ref"} It has a 4‐week recall period. The 5 domains of the SAQ include physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life. Each domain ranges from 0 to 100 points, with higher scores indicating higher levels of functioning, fewer symptoms, and greater quality of life or treatment satisfaction. The SAQ has similar psychometric properties in men and women and to validly quantify angina frequency as compared with daily diaries. In this study, we used SAQ‐AF (SAQ Angina Frequency) score and SAQ‐QoL (SAQ Quality of Life) score.[24](#jah34896-bib-0024){ref-type="ref"}, [25](#jah34896-bib-0025){ref-type="ref"} For both SAQ‐AF and SAQ‐QoL scores, an increase of ≥10 points was considered a clinically significant improvement.[7](#jah34896-bib-0007){ref-type="ref"} Additionally, we used the SAQ‐SS (SAQ Summary Score), which summarizes the physical limitation, angina frequency, and quality‐of‐life domains, to assess patients' overall angina‐related health status.[26](#jah34896-bib-0026){ref-type="ref"}

Statistical Analysis {#jah34896-sec-0013}
--------------------

We used frequency and percentages to describe categorical variables and means with SD or medians with interquartile ranges to describe continuous variables. We compared baseline characteristics between women and men using chi‐squared tests, Student *t* tests, or Kruskall‐Wallis tests as appropriate. Mean SAQ‐AF, SAQ‐QoL, and SAQ‐SS at baseline and 12 months were calculated and plotted between women and men, and the change from baseline to 12 months was represented as density plots. Then, mean SAQ‐AF, SAQ‐QoL, and SAQ‐SS at baseline and 1 year were compared between women and men, as well as the proportion of patients free of angina (SAQ‐AF score=100). Similarly, we compared mean change from baseline to 1 year in SAQ‐AF, SAQ‐QoL, and SAQ‐SS, as well as the proportion of patients achieving clinically significant improvements from baseline in SAQ‐AF and SAQ‐QoL, between men and women. Likewise, all‐cause mortality, cardiac death, stroke, AMI, coronary revascularization and a composite of major adverse cardiac events within 1 year following PCI were compared between women and men.

We tested the distribution of health status at 12 months. Both SAQ‐QoL and SAQ‐SS were normally distributed. However, SAQ‐AF score was left‐skewed. Thus, we modeled SAQ‐QoL and SAQ‐SS using linear regressions to investigate the independent effect of sex on 1‐year health status. We also modeled the likelihood of being free of angina (SAQ‐AF score=100) and the likelihood of achieving clinical significantly improvement in SAQ‐AF score and SAQ‐QoL score using logistic regression. For each of these regressions, we started with an unadjusted model (model 0), which only included sex. Then, we incrementally adjusted for additional covariates. The first model (model 1) included model sociodemographics (age, marital status, education, working status, and health insurance). The second model (model 2) added risk factors and comorbidities (hypertension, diabetes mellitus, hyperlipidemia, smoking status, body mass index \>24 kg/m^2^, family history of CAD, previous CAD, previous AMI, previous PCI, previous coronary artery bypass graft, previous stroke, peripheral artery disease, and heart failure) to model 1. The third model (model 3) added clinical characteristics at admission (eGFR, acute heart failure, acute stroke, and extent of CAD) to model 2. The fourth model (model 4) added treatment factors (number of vessels treated during PCI, stent implanted, access site, and medication during hospitalization) to model 3. The fifth model (model 5) added in‐hospital complications (major bleeding, any bleeding, blood transfusion, stroke, AMI, target vessel revascularization, coronary artery bypass graft, and length of stay) to model 4. The sixth model (model 6) added baseline health status to model 5.

The proportion of missing data of health status at 1 year was 24.0% and 23.8% among patients with UA and stable CAD, respectively. Among this cohort, women had more patients with missing data at 1‐year health status than men. Baseline characteristics of those patients with complete health status data versus those with missing data at 1 year, overall and stratified by sex, among the cohorts are presented in Table [S1](#jah34896-sup-0001){ref-type="supplementary-material"}.

To minimize the effect of selection bias, we constructed a nonparsimonious, multivariable logistic regression model to determine the probability of having missing health status data. We then weighted each of the observed patients by inverse probability of the likelihood of having missing data to increase the contribution of the experience of those most likely to have missing follow‐up assessments.[27](#jah34896-bib-0027){ref-type="ref"} Given that the missing values of the covariates in each model were rare (\<2%), except for body mass index (\<20%), missing values for covariates were imputed using multiple imputation. Specifically, we replaced each missing value with a set of values generated from its predictive distribution, given the observed data, and repeated this procedure to generate multiple imputed data sets. Each imputed data set was then analyzed separately using the corresponding modeling methods, and the final results were obtained by combining across all imputed data sets using Rubin\'s rule to account for uncertainty of imputation. All comparisons were 2‐sided, with statistical significance defined as *P*\<0.05. Statistical analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC) and R software (version 3.4.1; R Foundation for Statistical Computing, Vienna, Austria).

Results {#jah34896-sec-0014}
=======

Study Population and Baseline Characteristics {#jah34896-sec-0015}
---------------------------------------------

A total of 2237 patients without AMI undergoing PCI were included. Baseline characteristics are shown in Table [1](#jah34896-tbl-0001){ref-type="table"}. Median age was 63 years (interquartile range, 55--70). Women comprised 33.4%. Women were older, more often single, had a lower level of education, and were less likely to be employed and have urban insurance compared with men. Women were also less likely to be smokers and have a history of AMI and more likely to have hypertension, diabetes mellitus, hyperlipidemia, and worse renal function. During hospitalization, there were no significant sex differences in the number of vessels treated, proportion of complete revascularization, as well as use of medications and occurrence of complications during hospitalization. Women had a longer length of stay than men.

###### 

Baseline Characteristics of Patients Without AMI Undergoing PCI Stratified by Sex

                                                       Overall (n=2237)   Men (n=1490)   Women (n=747)   Statistic   *P* Value
  ---------------------------------------------------- ------------------ -------------- --------------- ----------- -----------
  Sociodemographics                                                                                                  
  Age, y, mean (SD)                                    62.26 (10.0)       61.09 (10.4)   64.6 (8.9)      −8.362      \<0.0001
  Age, median (IQR)                                    63 (55, 70)        61 (54, 69)    65 (59, 71)     −8.362      \<0.0001
  Married, n (%)                                       2026 (90.6)        1402 (94.1)    624 (83.5)      64.948      \<0.0001
  Education (high school or higher education), n (%)   312 (13.9)         270 (18.1)     42 (5.6)        64.758      \<0.0001
  Currently/ever work, n (%)                           1915 (85.6)        1361 (91.3)    554 (74.2)      119.16      \<0.0001
  Health insurance, n (%)                                                                                16.819      0.0002
  Urban insurance                                      1543 (69)          1070 (71.8)    473 (63.3)                  
  Rural cooperative medical service/None               691 (30.9)         418 (28.1)     273 (36.5)                  
  Unknown                                              3 (0.1)            2 (0.2)        1 (0.1)                     
  Cardiac risk factors, n (%)                                                                                        
  Hypertension                                         1545 (69.1)        947 (63.6)     598 (80.1)      63.376      \<0.0001
  Diabetes mellitus                                    671 (30.0)         396 (26.6)     275 (36.8)      24.830      \<0.0001
  Hyperlipidemia                                       1113 (49.8)        712 (47.8)     401 (53.7)      6.9191      0.0085
  Current smoker                                       828 (37.0)         772 (51.8)     56 (7.5)        419.12      \<0.0001
  BMI ≥24 kg/m^2^                                      1133 (50.6)        754 (50.6)     379 (50.7)      0.0035      0.9529
  Family history of CAD                                253 (11.3)         162 (10.9)     91 (12.2)       0.8507      0.3564
  Medical history, n (%)                                                                                             
  Previous AMI                                         373 (16.7)         287 (19.3)     86 (11.5)       21.504      \<0.0001
  Previous PCI                                         373 (16.7)         274 (18.4)     99 (13.3)       9.4474      0.0021
  Previous CABG                                        15 (0.7)           10 (0.7)       5 (0.7)         0.0000      0.9961
  Previous stroke                                      356 (15.9)         205 (13.8)     151 (20.2)      15.497      0.0001
  Congestive heart failure                             772 (34.5)         493 (33.1)     279 (37.3)      3.9992      0.0455
  Clinical characteristics at admission, n (%)                                                                       
  eGFR \<60 mL/min per 1.73 m^2^                       245 (11.0)         123 (8.3)      122 (16.3)      33.3400     \<0.0001
  Acute heart failure                                  17 (0.8)           10 (0.7)       7 (0.9)         0.4666      0.4946
  Acute stroke                                         53 (2.4)           34 (2.3)       19 (2.5)        0.1472      0.7012
  Extent of CAD, n (%)                                                                                   2.9090      0.4059
  One‐vessel disease                                   961 (43.0)         655 (44.0)     306 (41.0)                  
  Two‐vessel disease                                   803 (35.9)         529 (35.5)     274 (36.7)                  
  Three‐vessel disease                                 458 (20.5)         298 (20)       160 (21.4)                  
  Nonobstructive                                       15 (0.7)           8 (0.5)        7 (0.9)                     
  LM disease, n (%)                                    119 (5.3)          83 (5.6)       36 (4.8)        0.5574      0.4553
  Treatments, n (%)                                                                                                  
  No. of vessels treated during PCI                                                                      5.6688      0.1289
  Zero‐vessel                                          12 (0.5)           9 (0.6)        3 (0.4)                     
  One‐vessel                                           1660 (74.2)        1090 (73.2)    570 (76.3)                  
  Two‐vessel                                           539 (24.1)         369 (24.8)     170 (22.8)                  
  Three‐vessel                                         26 (1.2)           22 (1.5)       4 (0.5)                     
  Complete vs incomplete revascularization                                                               1.4224      0.4911
  Complete                                             225 (10.1)         146 (9.8)      79 (10.6)                   
  Incomplete                                           1036 (46.3)        681 (45.7)     355 (47.5)                  
  Unknown                                              976 (43.6)         663 (44.5)     313 (41.9)                  
  Stent                                                                                                  0.9388      0.3326
  DES                                                  2114 (94.5)        1413 (94.8)    701 (93.8)                  
  BMS                                                  0 (0.0)            0 (0.0)        0 (0.0)                     
  Unknown                                              123 (5.5)          77 (5.2)       46 (6.2)                    
  Access site                                                                                            2.5136      0.2846
  Radial                                               2013 (90)          1345 (90.3)    668 (89.4)                  
  Femoral                                              172 (7.7)          107 (7.2)      65 (8.7)                    
  Others                                               52 (2.3)           38 (2.6)       14 (1.9)                    
  Medications during hospitalization, n (%)                                                                          
  Aspirin                                              2046 (91.5)        1357 (91.1)    689 (92.2)      0.8600      0.3537
  Clopidogrel/ticagrelor                               2226 (99.5)        1482 (99.5)    744 (99.6)      0.1862      0.6661
  Statins                                              2209 (98.7)        1469 (98.6)    740 (99.1)      0.8980      0.3433
  Beta‐blocker                                         1806 (80.7)        1197 (80.3)    609 (81.5)      0.4534      0.5007
  ACEI/ARB                                             1443 (64.5)        957 (64.2)     486 (65.1)      0.1504      0.6981
  In‐hospital complications, n (%)                                                                                   
  Major bleeding                                       1 (0)              0 (0)          1 (0.1)         1.9955      0.1578
  Any bleeding                                         88 (3.9)           55 (3.7)       33 (4.4)        0.6947      0.4046
  Blood transfusion                                    6 (0.3)            3 (0.2)        3 (0.4)         0.7460      0.3878
  Stroke                                               85 (3.8)           49 (3.3)       36 (4.8)        3.1892      0.0741
  AMI                                                  31 (1.4)           18 (1.2)       13 (1.7)        1.0314      0.3098
  TVR                                                  15 (0.7)           11 (0.7)       4 (0.5)         0.3072      0.5794
  CABG                                                 2 (0.1)            2 (0.1)        0 (0)           1.0036      0.3164
  Length of stay, mean (SD)                            10.2 (5.1)         9.9 (5.1)      10.7 (5.0)      3.7999      0.0001
  Length of stay, median (IQR)                         9 (7,12)           9 (7,12)       9 (7,13)        3.7999      0.0001

ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; BMI, body mass index; BMS, bare mental stent; CABG, coronary artery bypass grafting; CAD, coronary heart disease; DES, drug‐eluting stent; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LM, left main coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; TVR, target vessel revascularization.

Clinical Outcomes {#jah34896-sec-0016}
-----------------

At 1 year after PCI, the rate of all‐cause mortality was similar between men and women in this cohort (1.7% versus 1.5%; *P*=0.716). Similarly, the rate of the composite end point, major adverse cardiac events, did not differ significantly between women and men among this cohort (Table [2](#jah34896-tbl-0002){ref-type="table"}).

###### 

Clinical Outcomes of Patients Without AMI During 1 Year Post‐PCI Stratified by Sex

                                      Overall (n=2237)   Men (n=1490)   Women (n=747)   Statistic   *P* Value
  ----------------------------------- ------------------ -------------- --------------- ----------- -----------
  All‐cause death, n (%)              36 (1.6)           25 (1.7)       11 (1.5)        0.1324      0.7159
  Cardiac death, n (%)                21 (0.9)           14 (0.9)       7 (0.9)         0.0000      0.9954
  Nonfatal AMI, n (%)                 10 (0.4)           5 (0.3)        5 (0.7)         1.2455      0.2644
  Ischemic stroke, n (%)              12 (0.5)           7 (0.5)        5 (0.7)         0.3713      0.5423
  Coronary revascularization, n (%)   77 (3.4)           50 (3.4)       27 (3.6)        0.1002      0.7516
  MACE, n (%)                         111 (5.0)          72 (4.8)       39 (5.2)        0.1594      0.6897

AMI indicates acute myocardial infarction; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention.

Unadjusted Sex Difference in Health Status {#jah34896-sec-0017}
------------------------------------------

As shown in Table [3](#jah34896-tbl-0003){ref-type="table"} and Figures [1](#jah34896-fig-0001){ref-type="fig"} and [2](#jah34896-fig-0002){ref-type="fig"}, women had significantly lower baseline scores for SAQ‐AF (58.5±30.4 versus 62.2±30.4; *P*\<0.01), SAQ‐QoL (52.7±24.0 versus 57.1±23.7; *P*\<0.01), and SAQ‐SS (60.9±20.0 versus 66.3±19.3; *P*\<0.01). The proportion of patients without angina did not vary by sex (17.1% versus 20.3%; *P*=0.196). At 1 year, women had lower SAQ‐AF scores (mean±SD, 91.0±17.3 versus 93.9±13.3; *P*\<0.01), SAQ‐QoL scores (mean±SD, 67.3±23.0 versus 70.6±21.6; *P*\<0.01), SAQ‐SS (81.6±13.8 versus 84.8±11.9; *P*\<0.01) and a lower proportion of patients without angina (50.3% versus 57.1%; *P*\<0.01) as compared with men. Of note, AF scores improved from baseline to 1 year in both men and women, and there were no sex differences in the change of SAQ‐AF (33.9±33.5 versus 32.9±31.7; *P*=0.343) and SAQ‐QoL scores (13.6±31.3 versus 12.6±30.6; *P*=0.594) or the proportion of patients who had a clinically significant improvement in SAQ‐AF (54.6% versus 55.6%; *P*=0.254) and SAQ‐QoL scores (36.4% versus 37.8%; *P*=0.170). However, women had a larger improvement of SAQ‐SS (20.9±22.6 versus 18.5±21.3; *P*=0.007).

###### 

Health Status of Patients Without AMI at 1 Year Post‐PCI Stratified by Sex

                                                            Overall (n=2237)   Men (n=1490)   Women (n=747)   Statistics   *P* Value
  --------------------------------------------------------- ------------------ -------------- --------------- ------------ -----------
  SAQ‐AF score (mean, SD)                                                                                                  
  Baseline                                                  61.0 (30.4)        62.2 (30.4)    58.5 (30.4)     −2.7410      0.0061
  1 y                                                       93.0 (14.8)        93.9 (13.3)    91.0 (17.3)     −3.1800      0.0015
  Change from baseline to 1 y                               33.2 (32.2)        32.9 (31.7)    33.9 (33.5)     0.9479       0.3432
  Clinically significant improvement from baseline to 1 y   1237.0 (55.3)      829.0 (55.6)   408.0 (54.6)    2.7376       0.2544
  SAQ‐QoL score (mean, SD)                                                                                                 
  Baseline                                                  55.6 (23.9)        57.1 (23.7)    52.7 (24.00)    −4.0840      \<0.0001
  1 y                                                       69.5 (22.1)        70.6 (21.6)    67.3 (23.0)     −2.5980      0.0094
  Change from baseline to 1 y                               12.9 (30.8)        12.6 (30.6)    13.6 (31.3)     0.5327       0.5943
  Clinically significant improvement from baseline to 1 y   835.0 (37.3)       563.0 (37.8)   272.0 (36.4)    3.5413       0.1702
  SAQ‐SS score (mean, SD)                                                                                                  
  Baseline                                                  64.5 (19.7)        66.3 (19.3)    60.9 (20.0)     −5.8790      \<0.0001
  1 y                                                       83.7 (12.6)        84.8 (11.9)    81.6 (13.8)     −4.1490      \<0.0001
  Change from baseline to 1 y                               19.3 (21.8)        18.5 (21.3)    20.9 (22.6)     2.6952       0.0070
  The patients without angina (SAQ‐AF score=100), n (%)                                                                    
  Baseline                                                  430.0 (19.2)       302.0 (20.3)   128.0 (17.1)    3.2592       0.1960
  1 y                                                       1227.0 (54.9)      851.0 (57.1)   376.0 (50.3)    9.8420       0.0073

AMI indicates acute myocardial infarction; PCI, percutaneous coronary intervention, SAQ‐AF, Seattle Angina Questionnaire Angina Frequency; SAQ‐QoL, Seattle Angina Questionnaire Quality of Life; SAQ‐SS, Seattle Angina Questionnaire Summary Score.

![Mean Seattle Angina Questionnaire (SAQ) scores stratified by sex at baseline and 1 year.](JAH3-9-e014421-g001){#jah34896-fig-0001}

![Distribution of Seattle Angina Questionnaire (SAQ) scores stratified by sex at baseline, 1 year, and the change form baseline to 1 year.](JAH3-9-e014421-g002){#jah34896-fig-0002}

Independent Association of Sex With 1‐Year Health Status Scores and Clinically Significant Improvement in Health Status {#jah34896-sec-0018}
-----------------------------------------------------------------------------------------------------------------------

Among the 2237 patients without AMI at baseline, 535 (23.9%) did not have follow‐up health status scores at 1 year. By fitting model 0 (ie, unadjusted model where sex is the only risk factor), women had −3.5 and −3.4 points lower in SAQ‐QoL scores and SAQ‐SS, respectively, as compared with men (95% CI for parameter coefficients, −5.7 to −1.2 and −4.6 to −2.1, respectively; Figure** ** [3](#jah34896-fig-0003){ref-type="fig"}). After adjusting for potential confounders, women still had significantly lower SAQ‐QoL scores (−3.2 points; 95% CI, −5.9 to −0.5) and SAQ‐SS (−2.7 points, 95% CI −4.2 to −1.2) at 1 year compared with men. Similarly, women were less likely to be free of angina after PCI as compared with men, even after adjusting for confounders (odds ratio, 0.63; 95% CI, 0.49--0.81). After adjusting for confounders, women were less likely to achieve clinically significant improvement in SAQ‐AF (odds ratio, 0.67; 95% CI, 0.45--1.00) and SAQ‐QoL scores (odds ratio, 0.73; 95% CI, 0.56--0.96) as compared with men (Figure** ** [4](#jah34896-fig-0004){ref-type="fig"}).

![Independent effect of sex on health status at 1 year post‐PCI among patients without AMI. (**A**) Possibility of being free of angina (Seattle Angina Questionnaire Angina Frequency score=100 vs \<100). (**B**) Seattle Angina Questionnaire Quality of Life score. (**C**) Seattle Angina Questionnaire Summary Score. AMI indicates acute myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SAQ, Seattle Angina Questionnaire.](JAH3-9-e014421-g003){#jah34896-fig-0003}

![Independent effect of sex on clinically significant improvement in health status from baseline to 1 year post‐PCI among the patients without AMI. (**A**) Possibility of achieving clinically significant improvement in SAQ‐AF score; (**B**) Possibility of achieving clinically significant improvement in SAQ‐QoL score. Seattle Angina Questionnaire summary score. AMI indicates acute myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; SAQ, Seattle Angina Questionnaire; SAQ‐AF, Seattle Angina Questionnaire Angina Frequency; SAQ‐QoL, Seattle Angina Questionnaire Quality of Life.](JAH3-9-e014421-g004){#jah34896-fig-0004}

Discussion {#jah34896-sec-0019}
==========

To our knowledge, this is the first study to explore sex differences in long‐term health status outcomes following PCI among patients without AMI in China. Among this cohort recruited from real‐word practice, women were more likely to be older and have poorer socioeconomic conditions and more cardiovascular risk factors. Nevertheless, there were no significant differences in treatment and 1‐year clinical outcomes by sex. In this context, although women had lower baseline scores of health status, there were no clinically significant differences in unadjusted health status scores at 1 year or likelihood to achieve clinically significant improvements in health status. However, after adjustment for important confounders, women had lower health status scores at 1 year and were less likely to be free of angina or to achieve clinically significant improvements in health status 1 year after PCI. Our findings provide a more complete picture of sex differences in health status outcomes after PCI among stable patients. This information is important for identifying the opportunities for improvement in the care of coronary artery disease for women without AMI.

In our study, we used patients without AMI, including those labeled as UA and stable CAD, as our study population. In real practice, the diagnosis of UA is increasingly controversial. More patients labeled with UA previously were diagnosed as non--ST‐segment--elevation MI with the use of troponin, particularly high‐sensitivity troponin, resulting in uncertainty of the diagnosis of UA and decreased risk of this cohort. Overdiagnosis of UA may occur because of external factors, such as reporting appropriateness or differences in reimbursement.[28](#jah34896-bib-0028){ref-type="ref"} Therefore, assessing health status outcomes after PCI among this clearly defined population may provide practical insight for real clinical practice.

We observed slightly lower average unadjusted 1‐year SAQ‐AF and SAQ‐QoL scores in women compared with men; however, the difference did not reach the threshold for what is defined as a clinically significant difference, given that a mean difference of \>5 points between groups is considered clinically significant.[29](#jah34896-bib-0029){ref-type="ref"} Nevertheless, we observed that women had lower health status scores in symptoms and quality of life at 1 year and were less likely to be free of angina after PCI. Previous studies have shown that observed lower scores at 1 year is largely attributable to lower baseline scores.[13](#jah34896-bib-0013){ref-type="ref"}, [30](#jah34896-bib-0030){ref-type="ref"} However, these sex differences persisted even after adjustment for covariates and baseline health status in this study. Several potential reasons may account for these findings. First, intravascular ultrasound/near infrared spectroscopy demonstrated that there were no sex differences in plaque morphology in stable patients.[31](#jah34896-bib-0031){ref-type="ref"}, [32](#jah34896-bib-0032){ref-type="ref"} However, women are more likely to have coronary microvascular dysfunction, even in those with obstructive CAD. Any symptoms attributable to microvascular dysfunction, cannot be completely relieved by PCI. Accordingly, quality‐of‐life scores are usually lower in symptomatic patients compared with their asymptomatic counterparts.[33](#jah34896-bib-0033){ref-type="ref"} Second, in this cohort, women had poorer educational status, which may be related to access to care and poor adherence to medication for secondary prevention after discharge. This could partly account for higher proportion of patients with angina and worse health status outcome at 1 year. Further studies on other psychosocial factors, such as depression, anxiety, and return to work, are needed to clarify the mechanisms for this difference in health status between women and men.

Although women had slightly lower scores in health status outcomes at baseline and 1 year, we found that women achieved similar magnitude of benefit from PCI in reducing frequency of angina and quality of life, even slightly greater improvement in overall health status, as compared with men. However, after adjustment of important covariates particularly baseline health status, risk factors, and comorbidities, female sex was associated with less likelihood to derive improvements in health status. The mechanism is not clear. Overall, in this cohort, women had lower baseline scores in health status and more risk factors and comorbidities, as compared with men, which were considered as the strongest factors for improvement after PCI.[34](#jah34896-bib-0034){ref-type="ref"} This higher likelihood of improvement was offset by the effect of female sex, resulting in a similar likelihood of improvement between women and men. These findings could be valuable for physicians treating women with PCI aiming to increase their quality of life as they treat men when this procedure is indicated. On the other hand, additional intervention may be needed to achieve the therapeutic goal of stable CAD care and reduce the disparity in outcomes between men and women.

Limitations {#jah34896-sec-0020}
-----------

The findings of this study should be interpreted in the context of several limitations. First, similar to other longitudinal, observational studies, such as TRIUMPH (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) and PREMIER (Prospective Registry Evaluating Outcomes After Myocardial Infarctions: Events and Recovery),[35](#jah34896-bib-0035){ref-type="ref"}, [36](#jah34896-bib-0036){ref-type="ref"} we could only enroll and follow up patients who consented to participate in the study. Hence, our findings may not generalize to all patients without AMI. Second, 23.9% of patients were missing health status data. To prevent potential biased estimation of sex differences in health status outcomes, we estimated the potential bias by performing a sensitivity analysis comparing baseline characteristics for men and women with and without complete health status data (Table [S1](#jah34896-sup-0001){ref-type="supplementary-material"}). Furthermore, we constructed nonparsimonious, multivariable logistic regression models to determine the probability of having missing data. We then weighted each of the observed patients by inverse probability of the likelihood to have missing data, so that we preferentially weighted the experience of those most like the patients who were missing follow‐up assessments. Additionally, in this study, telephone interviews were conducted when in‐person interviews were not feasible, and patient‐reported outcomes, such as SAQ, were assessed. However, if the patients' relatives answered the call, the patient‐reported outcomes would not be asked and assessed. Thus, the lack of follow‐up data for these patients was primarily attributed to relevant questions not asked when the patients' relatives completed the interview (469; 21.0%), rather than that they definitely had worse clinical outcomes. Thus, the effect of missing data on the result we estimated was small. Third, we did not collect information on additional treatments or comorbidities within 1 year after PCI, which could potentially affect patients' 1‐year health status. Finally, the Chinese PEACE (Patient‐centered Evaluative Assessment of Cardiac Events) prospective study was conducted 6 years ago; the analysis in this study may not completely reflect the current situation because of the change of treatment pattern and socioeconomic conditions.

Conclusions {#jah34896-sec-0021}
===========

There was no clinically significant difference in 1‐year health status outcomes and improvement in health status by sex among patients without AMI following PCI. However, women had poorer 1‐year health status and a lower likelihood of deriving clinically improvement in health status. Further studies are needed to clarify the association between sex and health status following PCI.
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